Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Oct 5;2015(10):CD010902.
doi: 10.1002/14651858.CD010902.pub2.

Oral nonsteroidal anti-inflammatory drugs for neuropathic pain

R Andrew Moore  1 , Ching-Chi Chi, Philip J Wiffen, Sheena Derry, Andrew S C Rice
Affiliations

Oral nonsteroidal anti-inflammatory drugs for neuropathic pain

R Andrew Moore et al. Cochrane Database Syst Rev. .

Abstract

Background: Although often considered to be lacking adequate evidence, nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used in the management of neuropathic pain. Previous surveys found 18% to 47% of affected people reported using NSAIDs specifically for their neuropathic pain, although possibly not in the United Kingdom (UK).

Objectives: To assess the analgesic efficacy of oral NSAIDs for chronic neuropathic pain in adults, when compared to placebo or another active intervention, and the adverse events associated with its use in clinical trials.

Search methods: We searched CENTRAL, MEDLINE, and EMBASE from inception to 29 May 2015, together with reference lists of retrieved papers and reviews, and an online trials registry.

Selection criteria: We included randomised, double-blind studies of two weeks duration or longer, comparing any oral NSAID with placebo or another active treatment in chronic neuropathic pain.

Data collection and analysis: Two review authors independently searched for studies, extracted efficacy and adverse event data, and examined issues of study quality. We did not carry out any pooled analysis.

Main results: We included two studies involving 251 participants with chronic low back pain with a neuropathic component or postherpetic neuralgia; 209 of these participants were involved in a study of an experimental NSAID not used in clinical practice, and of the remaining 42, only 16 had neuropathic pain. This represented only third tier evidence, and was of very low quality. There was no indication of any significant pain reduction with NSAIDs. Adverse event rates were low, with insufficient events for any analysis.

Authors' conclusions: There is no evidence to support or refute the use of oral NSAIDs to treat neuropathic pain conditions.

PubMed Disclaimer

Conflict of interest statement

RAM has no conflicts relating to this review or any similar product.

C‐CC has no conflicts relating to this review or any similar product.

PW has no conflicts relating to this review or any similar product.

SD has no conflicts relating to this review or any similar product.

ASCR has no conflicts relating to this review or any similar product.

Figures

1
1
Flow diagram.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
See this image and copyright information in PMC

Update of

  • doi: 10.1002/14651858.CD010902

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Romano 2009 {published data only}
    1. Romanò CL, Romanò D, Bonora C, Mineo G. Pregabalin, celecoxib, and their combination for treatment of chronic low‐back pain. Journal of Orthopaedics and Traumatology 2009;10(4):185‐91. [DOI: 10.1007/s10195-009-0077-z] - DOI - PMC - PubMed
Shackelford 2009 {published data only}
    1. Shackelford S, Rauck R, Quessy S, Blum D, Hodge R, Philipson R. A randomized, double‐blind, placebo‐controlled trial of a selective COX‐2 inhibitor, GW406381, in patients with postherpetic neuralgia. Journal of Pain 2009;10(6):654‐60. [DOI: 10.1016/j.jpain.2009.01.328] - DOI - PubMed

References to studies excluded from this review

Cohen 1987 {published data only}
    1. Cohen KL, Harris S. Efficacy and safety of nonsteroidal anti‐inflammatory drugs in the therapy of diabetic neuropathy. Archives of Internal Medicine 1987;147(8):1442‐4. [DOI: 10.1001/archinte.1987.00370080078016] - DOI - PubMed
Dellemijn 1994 {published data only}
    1. Dellemijn PL, Verbiest HB, Vliet JJ, Roos PJ, Vecht CJ. Medical therapy of malignant nerve pain. A randomised double‐blind explanatory trial with naproxen versus slow‐release morphine. European Journal of Cancer 1994;30A(9):1244‐50. [PUBMED: 7999406] - PubMed
Jaffé 1974 {published data only}
    1. Jaffé G. A double‐blind, between patient comparison of alclofenac (‘Prinalgin’)and indomethacin in the treatment of low back pain and sciatica. Current Medical Research and Opinion 1974;2(7):424‐9. [PUBMED: 4281380] - PubMed
Patarica‐Huber 2011 {published data only}
    1. Patarica‐Huber E, Boskov N, Pjevic M. Multimodal approach to therapy‐related neuropathic pain in breast cancer. Journal of B.U.ON. 2011;16(1):40‐5. [PUBMED: 21674848] - PubMed
Pop‐Busui 2015 {published data only}
    1. Pop‐Busui R. Pilot study to determine effects of salsalate in type 1 diabetes and painful peripheral neuropathy (SALP). clinicaltrials.gov/ct2/show/NCT01480297 (accessed 5 June 2015) 2015.
Solak 2007 {published data only}
    1. Solak O, Metin M, Esme H, Solak O, Yaman M, Pekcolaklar A, et al. Effectiveness of gabapentin in the treatment of chronic post‐thoracotomy pain. European Journal of Cardio‐thoracic Surgery 2007;32(1):9‐12. [DOI: 10.1016/j.ejcts.2007.03.022] - DOI - PubMed
Videman 1984 {published data only}
    1. Videman T, Osterman K. Double‐blind parallel study of piroxicam versus indomethacin in the treatment of low back pain. Annals of Clinical Research 1984;16(3):156‐60. [PUBMED: 6236738] - PubMed
Weber 1993 {published data only}
    1. Weber H, Holme I, Amlie E. The natural course of acute sciatica with nerve root symptoms in a double‐blind placebo‐controlled trial evaluating the effect of piroxicam. Spine 1993;18(11):1433‐8. [PUBMED: 8235813] - PubMed
Yu 2008 {published data only}
    1. Yu C, Chen Y, Mu Y, Chen X, Ding X, Ya W. Effect of oxycodone and acetaminophen on postherpetic neuralgia. Chinese Journal of New Drugs 2008;17(23):2061‐2.

References to ongoing studies

NCT01088256 {published data only}
    1. Maier C. Efficacy of etoricoxib on peripheral hyperalgesia. www.clinicaltrials.gov/ct2/show/NCT01088256 (accessed 5 June 2015) 2012.
NCT01264237 {published data only}
    1. Ratcliffe S. Evaluation of the efficacy, tolerability and safety of etoricoxib (Arcoxia) in patients with neuropathic pain. www.clinicaltrials.gov/ct2/show/NCT01264237 (accessed 5 June 2015) 2011.
NCT01838044 {published data only}
    1. Pfizer. Efficacy and safety study of celecoxib and pregabalin compared with celecoxib monotherapy, in patients with chronic low back pain having a neuropathic component. www.clinicaltrials.gov/ct2/show/NCT01838044 (accessed 5 June 2015) 2015.

Additional references

Baron 2012
    1. Baron R, Wasner G, Binder A. Chronic pain: genes, plasticity, and phenotypes. Lancet Neurology 2012;11(1):19‐21. [DOI: 10.1016/S1474-4422(11)70281-2] - DOI - PubMed
Boswell 2008
    1. Boswell DJ, Ostergaard K, Philipson RS, Hodge RA, Blum D, Brown JC, et al. Evaluation of GW406381 for treatment of osteoarthritis of the knee: two randomized, controlled studies. Medscape Journal of Medicine 2008;10(11):259. - PMC - PubMed
Bouhassira 2008
    1. Bouhassira D, Lantéri‐Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008;136(3):380‐7. [DOI: 10.1016/j.pain.2007.08.013] - DOI - PubMed
Calvo 2012
    1. Calvo M, Dawes JM, Bennett DL. The role of the immune system in the generation of neuropathic pain. Lancet Neurology 2012;11(7):629‐42. [DOI: 10.1016/S1474-4422(12)70134-5] - DOI - PubMed
Cochrane PaPaS Group 2012
    1. Cochrane Pain, Palliative and Supportive Care Group. PaPaS author and referee guidance. http://papas.cochrane.org/papas‐documents (accessed 5 June 2015) 2012.
Demant 2014
    1. Demant DT, Lund K, Vollert J, Maier C, Segerdahl M, Finnerup NB, et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double‐blind, placebo‐controlled phenotype‐stratified study. Pain 2014;155(11):2263‐73. [DOI: 10.1016/j.pain.2014.08.014] - DOI - PubMed
Derry 2012
    1. Derry S, Moore RA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2012, Issue 9. [DOI: 10.1002/14651858.CD010111] - DOI - PMC - PubMed
Derry 2013
    1. Derry S, Sven‐Rice A, Cole P, Tan T, Moore RA. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD007393.pub3] - DOI - PubMed
Derry 2014
    1. Derry S, Wiffen PJ, Moore RA, Quinlan J. Topical lidocaine for neuropathic pain in adults. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD010958.pub2] - DOI - PMC - PubMed
Di Franco 2010
    1. Franco M, Iannuccelli C, Atzeni F, Cazzola M, Salaffi F, Valesini G, et al. Pharmacological treatment of fibromyalgia. Clinical and Experimental Rheumatology 2010;28(6 Suppl 63):S110‐6. [PUBMED: 21176430] - PubMed
Dworkin 2008
    1. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 2008;9(2):105‐21. [DOI: 10.1016/j.jpain.2007.09.005] - DOI - PubMed
EMEA 2005
    1. EMEA public statement on the suspension of the marketing authorisation for Bextra (valdecoxib) in the European Union. ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/12/WC500... (accessed 25 Spetember 2015).
FDA 2004
    1. FDA Public Health Advisory: Safety of Vioxx. fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandPr... (accessed 25 September 2015).
Finnerup 2013
    1. Finnerup NB, Scholz J, Attal N, Baron R, Haanpää M, Hansson P, et al. Neuropathic pain needs systematic classification. European Journal of Pain 2013;17(7):953‐6. [DOI: 10.1002/j.1532-2149.2012.00282.x] - DOI - PubMed
Finnerup 2015
    1. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta‐analysis. Lancet Neurology 2015;14(2):162‐73. [DOI: 10.1016/S1474-4422(14)70251-0] - DOI - PMC - PubMed
Grosser 2011
    1. Grosser T, Smyth E. Chapter 34. Anti‐inflammatory, antipyretic, and analgesic agents; pharmacotherapy of gout. In: Brunton LL, Chabner BA, Knollmann BC editor(s). Goodman & Gilman's The Pharmacological Basis of Therapeutics. Available at accessmedicine.mhmedical.com/book.aspx?bookid=374 (accessed 5 Jun 2015). 12th Edition. New York: McGraw‐Hill, 2011. [ISBN: 978‐0‐07‐162442‐8]
Gustorff 2008
    1. Gustorff B, Dorner T, Likar R, Grisold W, Lawrence K, Schwarz F, et al. Prevalence of self‐reported neuropathic pain and impact on quality of life: a prospective representative survey. Acta Anaesthesiologica Scandinavica 2008;52(1):132‐6. [DOI: 10.1111/j.1399-6576.2007.01486.x] - DOI - PubMed
Hall 2008
    1. Hall GC, Carroll D, McQuay HJ. Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002‐2005. BMC Family Practice 2008;9:26. [DOI: 10.1186/1471-2296-9-26] - DOI - PMC - PubMed
Hall 2013
    1. Hall GC, Morant SV, Carroll D, Gabriel ZL, McQuay HJ. An observational descriptive study of the epidemiology and treatment of neuropathic pain in a UK general population. BMC Family Practice 2013;14:28. [DOI: 10.1186/1471-2296-14-28] - DOI - PMC - PubMed
Hasnie 2007
    1. Hasnie FS, Breuer J, Parker S, Wallace V, Blackbeard J, Lever I, et al. Further characterization of a rat model of varicella zoster virus‐associated pain: Relationship between mechanical hypersensitivity and anxiety‐related behavior, and the influence of analgesic drugs. Neuroscience 2007;144(4):1495‐508. [DOI: 10.1016/j.neuroscience.2006.11.029] - DOI - PMC - PubMed
Helfert 2015
    1. Helfert SM, Reimer M, Höper J, Baron R. Individualized pharmacological treatment of neuropathic pain. Clinical Pharmacology and Therapeutics 2015;97(2):135‐42. [DOI: 10.1002/cpt.19] - DOI - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org (accessed 5 June 2015).
Jadad 1996
    1. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials 1996;17(1):1‐12. [DOI: ] - PubMed
Jensen 2011
    1. Jensen TS, Baron R, Haanpää M, Kalso E, Loeser JD, Rice AS, et al. A new definition of neuropathic pain. Pain 2011; Vol. 152, issue 10:2204‐5. [DOI: 10.1016/j.pain.2011.06.017] - DOI - PubMed
Katusic 1991
    1. Katusic S, Williams DB, Beard CM, Bergstralh EJ, Kurland LT. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia: similarities and differences, Rochester, Minnesota,1945‐1984. Neuroepidemiology 1991;10(5‐6):276‐81. [PUBMED: 1798430] - PubMed
Kawakami 2002
    1. Kawakami M, Matsumoto T, Hashizume H, Kuribayashi K, Tamaki T. Epidural injection of cyclooxygenase‐2 inhibitor attenuates pain‐related behavior following application of nucleus pulposus to the nerve root in the rat. Journal of Orthopaedic Research 2002;20(2):376‐81. [DOI: 10.1016/S0736-0266(01)00114-0] - DOI - PubMed
Koopman 2009
    1. Koopman JS, Dieleman JP, Huygen FJ, Mos M, Martin CG, Sturkenboom MC. Incidence of facial pain in the general population. Pain 2009;147(1‐3):122‐7. [DOI: 10.1016/j.pain.2009.08.023] - DOI - PubMed
L'Abbé 1987
    1. L'Abbé KA, Detsky AS, O'Rourke K. Meta‐analysis in clinical research. Annals of Internal Medicine 1987;107:224‐33. - PubMed
Laine 2001
    1. Laine L. Approaches to nonsteroidal anti‐inflammatory drug use in the high‐risk patient. Gastroenterology 2001;120(3):594‐606. [DOI: 10.1053/gast.2001.21907] - DOI - PubMed
Liberati 2009
    1. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta‐analyses of studies that evaluate health care interventions: explanation and elaboration. Annals of Internal Medicine 2009;151(4):W65‐94. [DOI: 10.7326/0003-4819-151-4-200908180-00136] - DOI - PubMed
Lunn 2014
    1. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD007115.pub3] - DOI - PMC - PubMed
McQuay 1998
    1. McQuay H, Moore R. An Evidence‐based Resource for Pain Relief. 1st Edition. Oxford University Press, 1998. [ISBN: 978‐0192630483]
McQuay 2007
    1. McQuay HJ, Smith LA, Moore RA. Chronic Pain. In: Stevens A, Raftery J, Mant J, Simpson S editor(s). Health Care Needs Assessment. 3rd series. Oxford: Radcliffe Publishing, 2007. [ISBN: 978‐1‐84619‐063‐6]
Moore 1998
    1. Moore RA, Gavaghan D, Tramèr MR, Collins SL, McQuay HJ. Size is everything ‐ large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain 1998;78(3):209‐16. [DOI: 10.1016/S0304-3959(98)00140-7] - DOI - PubMed
Moore 2008
    1. Moore RA, Barden J, Derry S, McQuay HJ. Managing potential publication bias. In: McQuay HJ, Kalso E, Moore RA editor(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15‐24. [ISBN: 978‐0‐931092‐69‐5]
Moore 2009a
    1. Moore RA, Straube S, Wiffen PJ, Derry S, McQuay HJ. Pregabalin for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD007076.pub2] - DOI - PMC - PubMed
Moore 2009b
    1. Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta‐analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases 2010;69(2):374‐9. [DOI: ] - PMC - PubMed
Moore 2010a
    1. Moore RA, Eccleston C, Derry S, Wiffen P, Bell RF, Straube S, et al. "Evidence" in chronic pain ‐ establishing best practice in the reporting of systematic reviews. Pain 2010;150(3):386‐9. [DOI: 10.1016/j.pain.2010.05.011] - DOI - PubMed
Moore 2010b
    1. Moore RA, Smugar SS, Wang H, Peloso PM, Gammaitoni A. Numbers‐needed‐to‐treat analyses‐‐do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo‐controlled chronic low back pain trials. Pain 2010;151(3):592‐7. [DOI: 10.1016/j.pain.2010.07.013] - DOI - PubMed
Moore 2010c
    1. Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta‐analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Annals of the Rheumatic Diseases 2010;69(2):374‐9. [DOI: 10.1136/ard.2009.107805] - DOI - PMC - PubMed
Moore 2010d
    1. Moore RA, Straube S, Paine J, Phillips CJ, Derry S, McQuay HJ. Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain 2010;149(2):360‐4. [DOI: 10.1016/j.pain.2010.02.039] - DOI - PubMed
Moore 2011a
    1. Moore RA, Straube S, Paine J, Derry S, McQuay HJ. Minimum efficacy criteria for comparisons between treatments using individual patient meta‐analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction. Pain 2011;152(5):982‐9. [DOI: 10.1016/j.pain.2010.11.030] - DOI - PubMed
Moore 2011b
    1. Moore RA, Mhuircheartaigh RJ, Derry S, McQuay HJ. Mean analgesic consumption is inappropriate for testing analgesic efficacy in post‐operative pain: analysis and alternative suggestion. European Journal of Anaesthesiology 2011;28(6):427‐32. [DOI: 10.1097/EJA.0b013e328343c569] - DOI - PubMed
Moore 2012a
    1. Moore RA, Straube S, Eccleston C, Derry S, Aldington D, Wiffen P, et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain 2012;153(2):265‐8. [DOI: 10.1016/j.pain.2011.10.004] - DOI - PubMed
Moore 2012b
    1. Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD008242.pub2] - DOI - PubMed
Moore 2013a
    1. Moore A, Derry S, Eccleston C, Kalso E. Expect analgesic failure; pursue analgesic success. BMJ 2013;346:f2690. [DOI: 10.1136/bmj.f2690] - DOI - PubMed
Moore 2013b
    1. Moore RA, Derry S, Taylor RS, Straube S, Phillips CJ. The costs and consequences of adequately managed chronic non‐cancer pain and chronic neuropathic pain. Pain Practice 2014; Vol. 14, issue 1:79‐94. [DOI: 10.1111/papr.12050] - DOI - PubMed
NICE 2013
    1. National Institute for Health and Care Excellence (NICE). Neuropathic pain ‐ pharmacological management: the pharmacological management of neuropathic pain in adults in non‐specialist settings, 2013. www.nice.org.uk/guidance/cg173 (accessed 5 June 2015).
O'Brien 2010
    1. O'Brien EM, Staud RM, Hassinger AD, McCulloch RC, Craggs JG, Atchison JW, et al. Patient‐centered perspective on treatment outcomes in chronic pain. Pain Medicine 2010;11(1):6‐15. [DOI: 10.1111/j.1526-4637.2009.00685.x] - DOI - PubMed
Rappaport 1994
    1. Rappaport ZH, Devor M. Trigeminal neuralgia: the role of self‐sustaining discharge in the trigeminal ganglion. Pain 1994;56(2):127‐38. [DOI: 10.1016/0304-3959(94)90086-8] - DOI - PubMed
Review Manager 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Seidel 2013
    1. Seidel S, Aigner M, Ossege M, Pernicka E, Wildner B, Sycha T. Antipsychotics for acute and chronic pain in adults. Cochrane Database of Systematic Reviews 2013, Issue 8. [DOI: 10.1002/14651858.CD004844.pub3] - DOI - PMC - PubMed
Straube 2008
    1. Straube S, Derry S, McQuay HJ, Moore RA. Enriched enrollment: definition and effects of enrichment and dose in trials of pregabalin and gabapentin in neuropathic pain. A systematic review. British Journal of Clinical Pharmacology 2008;66(2):266‐75. [DOI: 10.1111/j.1365-2125.2008.03200.x] - DOI - PMC - PubMed
Straube 2010
    1. Straube S, Derry S, Moore RA, Paine J, McQuay HJ. Pregabalin in fibromyalgia ‐ responder analysis from individual patient data. BMC Musculoskeletal Disorders 2010;11:150. [DOI: 10.1186/1471-2474-11-150] - DOI - PMC - PubMed
Sultan 2008
    1. Sultan A, Gaskell H, Derry S, Moore RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BMC Neurology 2008;8:29. [DOI: 10.1186/1471-2377-8-29] - DOI - PMC - PubMed
Torrance 2006
    1. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. Journal of Pain 2006;7(4):281‐9. [DOI: 10.1016/j.jpain.2005.11.008] - DOI - PubMed
Treede 2008
    1. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2008;70(18):1630‐5. [DOI: 10.1212/01.wnl.0000282763.29778.59] - DOI - PubMed
Varner 2009
    1. Varner J, Lomax M, Blum D, Quessy S. A randomized, controlled, dose‐ranging study investigating single doses of GW406381, naproxen sodium, or placebo in patients with acute pain after third molar tooth extraction. Clinical Journal of Pain 2009;25(7):577‐83. [DOI: 10.1097/AJP.0b013e3181a085fa] - DOI - PubMed
Vo 2009
    1. Vo T, Rice ASC, Dworkin RH. Non‐steroidal anti‐inflammatory drugs for neuropathic pain: How do we explain continued widespread use?. Pain 2009;143(3):169‐71. [DOI: 10.1016/j.pain.2009.03.013] - DOI - PubMed
von Hehn 2012
    1. Hehn CA, Baron R, Woolf CJ. Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron 2012;73(4):638‐52. [DOI: 10.1016/j.neuron.2012.02.008] - DOI - PMC - PubMed
Vos 2012
    1. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990‐2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2163‐96. [DOI: 10.1016/S0140-6736(12)61729-2] - DOI - PMC - PubMed
Wentz 2008
    1. Wentz AL, Jimenez TB, Dixon RM, Aurora SK, Gold M, CXA20008 Study Investigators. A double‐blind, randomized, placebo‐controlled, single‐dose study of the cyclooxygenase‐2 inhibitor, GW406381, as a treatment for acute migraine. European Journal of Neurology 2008;15(4):420‐7. [DOI: 10.1111/j.1468-1331.2008.02093.x] - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources